Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth
Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...
SWX: SDZ
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced...
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...
Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...
Sandoz Receives European Commission Approval for Biosimilars Wyost and Jubbonti
The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX:...
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...
Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva
Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars
The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...
Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case
Sandoz (SIX: SDZ), the Swiss-based pharmaceutical company, announced this week that its U.S. subsidiaries have...
Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri
Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...
Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment
Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...
AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market
AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...
Sandoz Invests in New Biosimilars and Penicillin API Production Sites in Europe
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced the opening of two new production sites...
Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance
Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered...
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...
Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers
Sandoz (SWX: SDZ), the generic and biosimilar drug maker set to separate from Novartis (NYSE:...